Study

Pan-tumor genomic biomarkers for personalization of PD-1 checkpoint blockade based immunotherapy

Study ID Alternative Stable ID Type
phs001572 Case Set

Study Description

Tumor mutation burden (TMB) and a T-cell-inflamed gene expression profile (GEP) independently predict clinical outcome in pembrolizumab-treated patients in 22 indications and stratify distinct targets of resistance biology.

Archive Link Archive Accession
dbGaP phs001572

Who archives the data?

There are no publications available